




Instance: composition-en-2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: CompositionUvEpi
Title: "Composition for defitelio Package Leaflet"
Description:  "Composition for defitelio Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2ca0df99b82dc3da3ea077d36f8da2cd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - defitelio"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Defitelio is and what it is used for </li>
<li>What you need to know before you are administered Defitelio </li>
<li>How you will be given Defitelio </li>
<li>Possible side effects </li>
<li>How to store Defitelio </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What defitelio is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What defitelio is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Defitelio is a medicine that contains the active substance defibrotide.  </p>
<p>It is used to treat a condition called hepatic veno-occlusive disease, in which the blood vessels in the 
liver become damaged and obstructed by blood clots. This can be caused by medicines that are given 
prior to a stem cell transplantation. </p>
<p>Defibrotide works by protecting the cells of the blood vessels and preventing or breaking down the 
blood clots.  </p>
<p>This medicine can be used in adults, and in adolescents, children and infants over one month of age. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Defitelio 
* if you are allergic to defibrotide or any of the other ingredients of this medicine (listed in 
section 6) 
* if you are using other medicines to break down blood clots such as tissue plasminogen activator.  </p>
<p>Warnings and precautions 
Talk to your doctor before using Defitelio: 
* if you are taking medicine that increases the risk of bleeding. 
* if you have heavy bleeding and need a blood transfusion. 
* if you are undergoing surgery. 
* if you have problems with blood circulation because your body cannot maintain a constant 
blood pressure. </p>
<p>Children and adolescents 
Defitelio is not recommended in children less than 1 month of age. </p>
<p>Other medicines and Defitelio 
Tell your doctor if you are taking medicines to prevent blood clotting such as acetylsalicylic acid, 
heparins, warfarin, dabigatran, rivaroxaban or apixaban or if you are taking anti-inflammatory 
medicines (e.g., ibuprofen, naproxen, diclofenac and other non-steroidal anti-inflammatory 
medicines). </p>
<p>Pregnancy and breast-feeding 
Do not use Defitelio if you are pregnant unless your disease requires treatment with Defitelio. 
If you are sexually active and you or your partner could become pregnant, you both must use effective 
contraception during treatment with Defitelio and for 1 week after stopping the treatment.  </p>
<p>Driving and using machines 
It is not expected that Defitelio will affect your ability to drive and use machines. </p>
<p>Defitelio contains sodium 
This medicine contains 20.4 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 1.02% of the recommended maximum daily dietary intake of sodium for an adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The treatment with Defitelio can be initiated and continuously supervised only by an experienced 
doctor in a hospital or in a specialised centre for stem cells transplantation. </p>
<p>It will be slowly injected (over a 2-hour period) into one of your veins. This is called an  intravenous 
infusion  or drip. </p>
<p>You will receive this treatment four times a day for at least 21 days or until your symptoms resolve. 
The recommended dose in children from one month to 18 years of age is the same as in adults. </p>
<p>If a dose of Defitelio has been forgotten 
As you will be given this medicine by a doctor or a nurse it is unlikely that a dose will be missed. 
However, tell your doctor or healthcare professional if you think that a dose has been forgotten. You 
must not be given a double dose to make up for a missed dose. 
If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. For 
patients treated with Defitelio the following side effects were reported. </p>
<p>If you experience any of these side effects, you should contact your doctor immediately. </p>
<p>Very common (may affect more than 1 in 10 people) 
* low blood pressure  </p>
<p>Common (may affect up to 1 in 10 people) 
* bleeding in general 
* bleeding from the nose 
* bleeding in the brain 
* bleeding in the gut 
* vomiting blood </p>
<ul>
<li>bleeding in the lungs </li>
<li>bleeding from the infusion line </li>
<li>blood in the urine </li>
<li>bleeding from the mouth </li>
<li>bleeding into the skin </li>
<li>coagulopathy (disturbance of blood clotting) </li>
<li>nausea </li>
<li>vomiting </li>
<li>diarrhoea </li>
<li>rash </li>
<li>itching </li>
<li>fever </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people) 
* bleeding from the eye 
* blood in the stool 
* bleeding at the site of injection 
* localized blood collection out of the vessel (hematoma) in the brain 
* haemothorax (accumulation of blood in the area between the heart and the lung) 
* bruising 
* allergic reactions (you might experience skin reactions such as a rash 
* severe allergic reaction (you might experience swelling of the hands, face, lips, tongue or throat, 
difficulty in breathing). </p>
<p>Children and adolescents 
Side effects in children (1 month to 18 years old) are expected to be similar in type, severity and 
frequency and no other special precautions are needed. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use Defitelio after the expiry date which is stated on the carton and vial label after EXP. The 
expiry date refers to the last day of that month.  </p>
<p>Store below 25  C. Do not freeze. </p>
<p>Once diluted for use the infusion storage should not exceed 24 hours at 2  C - 8  C unless dilution has 
taken place in controlled and validated aseptic conditions. </p>
<p>Defitelio should not be used if the solution is cloudy or contains particles. </p>
<p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines 
you no longer use. These measures will help protect the environment.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Defitelio contains 
* The active substance is defibrotide. Each 2.5 mL vial contains 200 mg defibrotide and each mL 
solution contains 80 mg defibrotide. 
* The other ingredients are sodium citrate dihydrate, hydrochloric acid and sodium hydroxide 
(both for pH-adjustment) and water for injections (see section 2  Defitelio contains sodium ).  </p>
<p>What Defitelio looks like and contents of the pack 
Defitelio is a clear light yellow to brown concentrate for solution for infusion (sterile concentrate), 
free from particulate matter or turbidity. </p>
<p>One carton contains 10 glass vials with 2.5 mL of concentrate each. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Gentium S.r.l<br />
Piazza XX Settembre, 2 
22079 Villa Guardia (Como) 
Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>AT   BE   BG   CY   CZ   DE   DK   EE   EL   ES   FI   FR   HR   HU   IE   IS   IT   LT 
  LU   LV   MT   NL   NO   PL   PT   RO   SE   SK   SL   UK(NI) </p>
<p>Jazz Pharmaceuticals Ireland Limited<br />
Tel: +353 1 968 1(local phone number within Republic of Ireland) 
(outside Republic of Ireland may include an international phone call charge) 
Email: medinfo-int@jazzpharma.com </p>
<p>This leaflet was last revised in:. </p>
<p>This medicine has been authorised under  exceptional circumstances . This means that because of the 
rarity of this disease and for ethical reasons it has been impossible to perform placebo-controlled 
clinical studies and to get complete information on this medicine. </p>
<p>The European Medicines Agency will review any new information on this medicine every year and 
this leaflet will be updated as necessary. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: CompositionUvEpi
Title: "Composition for defitelio Package Leaflet"
Description:  "Composition for defitelio Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2ca0df99b82dc3da3ea077d36f8da2cd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - defitelio"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du får Defitelio 
3. Sådan får du Defitelio 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What defitelio is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What defitelio is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Defitelio er et lægemiddel, der indeholder det aktive stof defibrotid.  </p>
<p>Det anvendes til behandling af hepatisk venookklusiv sygdom, hvor blodkarrene i leveren bliver 
beskadiget og tilstoppet af blodpropper. Sygdommen kan forårsages af de lægemidler, der gives før en 
stamcelletransplantation. </p>
<p>Defibrotid virker ved at beskytte cellerne i blodkarrene og forhindre dannelsen af blodpropper eller 
nedbryde dem.  </p>
<p>Dette lægemiddel kan anvendes til voksne og unge, børn og spædbørn over 1 måned.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Defitelio </p>
<ul>
<li>
<p>hvis du er allergisk over for defibrotid eller et af de øvrige indholdsstoffer i Defitelio (angivet i 
afsnit 6) </p>
</li>
<li>
<p>hvis du bruger anden medicin, der opløser blodpropper, såsom vævsplasminogenaktivator. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du bruger Defitelio: </p>
<ul>
<li>
<p>hvis du tager medicin, som øger risikoen for blødning </p>
</li>
<li>
<p>hvis du bløder kraftigt og har behov for blodtransfusion  </p>
</li>
<li>
<p>hvis du får foretaget en operation  </p>
</li>
<li>
<p>hvis du har problemer med kredsløbet, fordi din krop har svært ved at holde blodtrykket 
konstant.  </p>
</li>
</ul>
<p>Børn og unge 
Det frarådes at anvende Defitelio hos spædbørn under 1 måned. </p>
<p>Brug af anden medicin sammen med Defitelio 
Sig det til lægen, hvis du får lægemidler til forebyggelse af blodpropper, såsom acetylsalicylsyre, 
hepariner, warfarin, dabigatran, rivaroxaban eller apixaban, eller hvis du får antiinflammatoriske 
lægemidler (f.eks. ibuprofen, naproxen, diclofenac eller andre ikke-steroide antiinflammatoriske 
lægemidler).  </p>
<p>Graviditet og amning 
Brug ikke Defitelio, hvis du er gravid, medmindre din sygdom gør behandling med Defitelio 
nødvendig.<br />
Hvis du er seksuelt aktiv, og du eller din partner kan blive gravid, skal I begge bruge effektiv 
prævention under behandlingen med Defitelio og en uge efter at være ophørt med behandlingen.  </p>
<p>Trafik- og arbejdssikkerhed 
Defitelio forventes ikke at påvirke din evne til at føre motorkøretøj og betjene maskiner. </p>
<p>Defitelio indeholder natrium 
Dette lægemiddel indeholder 20,4 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
hætteglas. Dette svarer til 1,02 % af den anbefalede maksimale daglige indtagelse af natrium for en 
voksen.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Behandlingen med Defitelio kan kun iværksættes og løbende overvåges af en erfaren læge på et 
hospital eller på et specialcenter for stamcelletransplantation.  </p>
<p>Lægemidlet vil blive injiceret langsomt (i løbet af to timer) i en af dine vener. Dette kaldes “intravenøs 
infusion" eller drop.  </p>
<p>Du vil få denne behandling fire gange dagligt i mindst 21 dage, eller indtil dine symptomer svinder.<br />
Den anbefalede dosis til børn fra en måned til 18 år er den samme som til voksne. </p>
<p>Hvis en dosis af Defitelio er blevet sprunget over 
Da du får dette lægemiddel af en læge eller sygeplejerske, er det usandsynligt, at der vil blive 
oversprunget en dosis. Hvis du alligevel mener, at en dosis er blevet sprunget over, skal du sige det til 
lægen eller sundhedspersonalet. Du må ikke få en dobbeltdosis som erstatning for en glemt dosis. 
Spørg lægen, sygeplejersken eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Nedenstående bivirkninger er indberettet for patienter, der har fået behandling med Defitelio. </p>
<p>Hvis du kommer ud for nogen af disse bivirkninger, skal du straks kontakte lægen. </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 behandlede): </p>
<ul>
<li>lavt blodtryk </li>
</ul>
<p>Almindelige (kan forekomme hos indtil 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>blødning generelt </p>
</li>
<li>
<p>næseblod  </p>
</li>
<li>
<p>hjerneblødning </p>
</li>
<li>
<p>tarmblødning </p>
</li>
<li>
<p>blodigt opkast </p>
</li>
<li>
<p>blødning i lungerne </p>
</li>
<li>
<p>blødning ved infusionsslangen </p>
</li>
<li>
<p>blod i urinen  </p>
</li>
<li>
<p>blødning fra munden </p>
</li>
<li>
<p>blødning i huden  </p>
</li>
<li>
<p>koagulopati (forstyrrelser i blodets størkning)  </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>feber.  </p>
</li>
</ul>
<p>Ikke almindelige (forekommer hos indtil 1 ud af 100 behandlede) </p>
<ul>
<li>
<p>blødning fra øjnene </p>
</li>
<li>
<p>blod i afføringen  </p>
</li>
<li>
<p>blødning på injektionsstedet  </p>
</li>
<li>
<p>lokaliseret blodansamling uden for blodkarrene (hæmatom) i hjernen </p>
</li>
<li>
<p>hæmothorax (blodansamling i rummet mellem hjertet og lungerne) </p>
</li>
<li>
<p>blå mærker </p>
</li>
<li>
<p>allergiske reaktioner (f.eks. reaktioner på huden såsom udslæt) </p>
</li>
<li>
<p>svær allergisk reaktion (f.eks. hævede hænder, ansigt, læber, tunge og hals, 
vejrtrækningsbesvær). </p>
</li>
</ul>
<p>Børn og unge 
Bivirkningerne hos børn (fra 1 måned til 18 år) forventes at være af samme type, sværhed og 
hyppighed som hos voksne, og der kræves ingen andre særlige forsigtighedsregler.  </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store defitelio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store defitelio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar Defitelio utilgængeligt for børn. </p>
<p>Brug ikke Defitelio efter den udløbsdato, der står på kartonen og hætteglassets etiket efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned.  </p>
<p>Opbevares ved temperaturer under 25 °C. Må ikke nedfryses. </p>
<p>Efter klargøring af lægemidlet til brug må infusionsvæsken højst opbevares i 24 timer ved 2 til 8 °C, 
medmindre fortynding har fundet sted under kontrollerede og validerede aseptiske betingelser.  </p>
<p>Defitelio må ikke anvendes, hvis opløsningen er uklar eller indeholder partikler. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Defitelio indeholder: </p>
<ul>
<li>
<p>Aktivt stof: defibrotid. Hvert 2,5 ml hætteglas indeholder 200 mg defibrotid, og hver ml 
opløsning indeholder 80 mg defibrotid. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: natriumcitrat (dihydrat), saltsyre og natriumhydroxid (begge til pH-
justering) og vand til injektionsvæsker (se afsnit 2 “Defitelio indeholder natrium"). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Defitelio er et bleggult til brunt koncentrat til infusionsvæske, opløsning (sterilt koncentrat), og er fri 
for partikler eller uklarhed. 
En kartonæske med 10 hætteglas med hver 2,5 ml koncentrat. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Gentium S.r.l<br />
Piazza XX Settembre, 2 
22079 Villa Guardia (Como) 
Italien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>AT - BE - BG - CY - CZ - DE - DK - EE - EL - ES - FI - FR - HR 
- HU - IE - IS - IT - LT - LU - LV - MT - NL - NO - PL - PT - 
RO - SE - SK - SL - UK(NI) </p>
<p>Jazz Pharmaceuticals Ireland Limited<br />
Tel: +353 1 968 1(lokalt telefonnummer i Irland) 
(der kan være internationale opkaldsafgifter på opkald uden for Irland)<br />
E-mail: medinfo-int@jazzpharma.com </p>
<p>Denne indlægsseddel blev senest ændret:  </p>
<p>Dette lægemiddel er godkendt under “særlige vilkår".  </p>
<p>Det betyder, at det af etiske grunde ikke har været muligt at udføre placebokontrollerede kliniske 
studier og opnå fuldstændig dokumentation for lægemidlet, fordi det anvendes til en sjælden sygdom. </p>
<p>Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. 
Der er også links til andre websteder om sjældne sygdomme og om, hvordan de behandles. </p>
<hr />         </div>"""      





                    
Instance: bundlepackageleaflet-en-2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for defitelio Package Leaflet for language en"
Description: "ePI document Bundle for defitelio Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-2ca0df99b82dc3da3ea077d36f8da2cd"
* entry[0].resource = composition-en-2ca0df99b82dc3da3ea077d36f8da2cd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2ca0df99b82dc3da3ea077d36f8da2cd"
* entry[=].resource = mp2ca0df99b82dc3da3ea077d36f8da2cd
                            
                    
Instance: bundlepackageleaflet-da-2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for defitelio Package Leaflet for language da"
Description: "ePI document Bundle for defitelio Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-2ca0df99b82dc3da3ea077d36f8da2cd"
* entry[0].resource = composition-da-2ca0df99b82dc3da3ea077d36f8da2cd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2ca0df99b82dc3da3ea077d36f8da2cd"
* entry[=].resource = mp2ca0df99b82dc3da3ea077d36f8da2cd
                            
                    



Instance: mp2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Defitelio 80 mg/mL concentrate for solution for infusion"
Description: "Defitelio 80 mg/mL concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/878/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Defitelio 80 mg/mL concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 2ca0df99b82dc3da3ea077d36f8da2cdListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "defitelio"

* status = #current
* mode = #working

* title = "List of all ePIs associated with defitelio"

* subject = Reference(mp2ca0df99b82dc3da3ea077d36f8da2cd)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#defitelio "defitelio"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-2ca0df99b82dc3da3ea077d36f8da2cd) // defitelio en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-2ca0df99b82dc3da3ea077d36f8da2cd) // defitelio da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-2ca0df99b82dc3da3ea077d36f8da2cd
InstanceOf: List

* insert 2ca0df99b82dc3da3ea077d36f8da2cdListRuleset
    